Home › Funds › Anson Funds Management LP › SLS
Anson Funds Management LP position in SLS
SELLAS LIFE SCIENCES GROUP I · Health Care
Anson Funds Management LP reported holding 3,100,000 shares of SLS (SELLAS LIFE SCIENCES GROUP I) in its Q3 2026 13F filing — a position valued at US$38.2M, representing 2.62% of its reported portfolio and ranking #8 among its reported holdings. Anson Funds Management LP has disclosed SLS holdings in 8 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Anson Funds Management LP's SLS position evolved
Anson Funds Management LP first disclosed a stake in SLS in Q1 2024 at 4,832,368 shares (US$4.9M). The position peaked in Q3 2026 at 3,100,000 shares, worth US$38.2M. Across 8 filings, Anson Funds Management LP increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,100,000 shares valued at US$38.2M — an increase of 2,300,000 shares quarter over quarter.. Notable position changes include a 536% increase in Q1 2025 (shares rose 103% over the following quarter), a 2094% increase in Q3 2025 (shares rose 134% over the following quarter), a 288% increase in Q3 2026 (shares fell 36% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 4.83M | $4.88M | New |
| Q3 2024 | 793.84K | $992.29K | New |
| Q4 2024 | 1.19M | $1.24M | Add |
| Q1 2025 | 7.58M | $8.19M | Add |
| Q2 2025 | 275.00K | $602.25K | Reduce |
| Q3 2025 | 6.03M | $9.71M | Add |
| Q2 2026 | 800.00K | $11.81M | New |
| Q3 2026 | 3.10M | $38.16M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SLS and 13F data
SLS (SELLAS LIFE SCIENCES GROUP I) is a Health Care company. 108 other funds we track also report a position in SLS — the largest reported positions include Sio Capital Management, LLC (US$18.2M), DAGCO, INC. (US$16.5M), Ikarian Capital, LLC (US$5.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SLS
- Sio Capital Management, LLC 1.23M sh · $18.17M · Q2 2026
- DAGCO, INC. 1.34M sh · $16.45M · Q3 2026
- Ikarian Capital, LLC 354.70K sh · $5.24M · Q2 2026
- Opus Capital Group, LLC 403.63K sh · $4.97M · Q3 2026
- Murchinson Ltd. 200.00K sh · $2.46M · Q3 2026
- Rosalind Advisors, Inc. 568.70K sh · $2.30M · Q2 2026
- FULCRUM WEALTH ADVISORS, LLC 85.45K sh · $1.05M · Q3 2026
- VISION FINANCIAL MARKETS LLC 57.00K sh · $701.67K · Q3 2026
- Marathon Trading Investment Management LLC 50.10K sh · $616.73K · Q3 2026
- INSTRUMENTAL WEALTH, LLC 44.91K sh · $552.89K · Q3 2026
More on Anson Funds Management LP
FAQ
How long has Anson Funds Management LP held SLS?
Anson Funds Management LP has disclosed SLS holdings in 8 of the last 11 reported quarters, going back to Q1 2024.
What is Anson Funds Management LP's current position in SLS?
As of Q3 2026, Anson Funds Management LP holds 3.10M shares of SLS (SELLAS LIFE SCIENCES GROUP I), valued at $38.16M, representing 2.62% of its reported portfolio and ranking #8.
Has Anson Funds Management LP been buying or selling SLS?
In the latest 13F filing (Q3 2026), Anson Funds Management LP increased its position in SLS. The position peaked in Q3 2026 at 3.10M shares.
Which other funds hold SLS?
Other major institutional holders of SLS include Sio Capital Management, LLC, DAGCO, INC., Ikarian Capital, LLC, among 108 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.